Treatment with intravenous immunoglobulins and methylprednisolone may significantly decrease loss of renal function in chronic-active antibody-mediated rejection
Abstract Background Chronic-active antibody mediated rejection (c-aABMR) is a major contributor to long-term kidney allograft loss. We conducted a retrospective analysis to establish the efficacy of treatment with intravenous immunoglobulins (IVIG) and pulse methylprednisolone (MP) of patients with...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-06-01
|
Series: | BMC Nephrology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12882-019-1385-z |
_version_ | 1819207364783374336 |
---|---|
author | Kasia A. Sablik Marian C. Clahsen-van Groningen Caspar W. N. Looman Jeffrey Damman Madelon van Agteren Michiel G. H. Betjes |
author_facet | Kasia A. Sablik Marian C. Clahsen-van Groningen Caspar W. N. Looman Jeffrey Damman Madelon van Agteren Michiel G. H. Betjes |
author_sort | Kasia A. Sablik |
collection | DOAJ |
description | Abstract Background Chronic-active antibody mediated rejection (c-aABMR) is a major contributor to long-term kidney allograft loss. We conducted a retrospective analysis to establish the efficacy of treatment with intravenous immunoglobulins (IVIG) and pulse methylprednisolone (MP) of patients with c-aABMR. Methods Sixty-nine patients, in the period 2005–2017, with the diagnosis (suspicious for) c-aABMR that were treated with IVIG and MP were included. Patients were administered three doses of 1 g intravenous MP combined with a single dose of IVIG (1 g/kg body weight). Primary outcome was the decline in allograft function one year post treatment. Responders to IVIG-MP therapy were defined by an eGFR one year after treatment which was at least 25% above the projected allograft function. Results Patients showed an average decline in eGFR of 9.8 ml/min/1.73m2 the year prior to treatment. Following treatment, a significant reduction (p < 0.001) in eGFR decline was observed (6.3 ml/min/1.73m2). Furthermore, a significant improvement in proteinuria was observed upon treatment (p < 0.001). Sixty-two percent (n = 43) of the patients were considered a responder and showed considerable slowing of graft function deterioration in the year after treatment (p < 0.001). Three and 5-year graft survival was significantly superior in responders. Conclusions More than 60% of patients with c-aABMR with a progressive decline in eGFR respond favorably to treatment with IVIG-MP resulting in a significant improvement of graft survival (Sablik, Am J Transplant 18, 2018). |
first_indexed | 2024-12-23T05:22:19Z |
format | Article |
id | doaj.art-7410a0f845f442bf84a515355d5e7a13 |
institution | Directory Open Access Journal |
issn | 1471-2369 |
language | English |
last_indexed | 2024-12-23T05:22:19Z |
publishDate | 2019-06-01 |
publisher | BMC |
record_format | Article |
series | BMC Nephrology |
spelling | doaj.art-7410a0f845f442bf84a515355d5e7a132022-12-21T17:58:39ZengBMCBMC Nephrology1471-23692019-06-012011910.1186/s12882-019-1385-zTreatment with intravenous immunoglobulins and methylprednisolone may significantly decrease loss of renal function in chronic-active antibody-mediated rejectionKasia A. Sablik0Marian C. Clahsen-van Groningen1Caspar W. N. Looman2Jeffrey Damman3Madelon van Agteren4Michiel G. H. Betjes5Erasmus Medical Center, Department of Nephrology & Transplantation, room Na2105Department of Pathology, Erasmus Medical CenterDepartment of Biostatistics, Erasmus Medical CenterDepartment of Pathology, Erasmus Medical CenterErasmus Medical Center, Department of Nephrology & Transplantation, room Na2105Erasmus Medical Center, Department of Nephrology & Transplantation, room Na2105Abstract Background Chronic-active antibody mediated rejection (c-aABMR) is a major contributor to long-term kidney allograft loss. We conducted a retrospective analysis to establish the efficacy of treatment with intravenous immunoglobulins (IVIG) and pulse methylprednisolone (MP) of patients with c-aABMR. Methods Sixty-nine patients, in the period 2005–2017, with the diagnosis (suspicious for) c-aABMR that were treated with IVIG and MP were included. Patients were administered three doses of 1 g intravenous MP combined with a single dose of IVIG (1 g/kg body weight). Primary outcome was the decline in allograft function one year post treatment. Responders to IVIG-MP therapy were defined by an eGFR one year after treatment which was at least 25% above the projected allograft function. Results Patients showed an average decline in eGFR of 9.8 ml/min/1.73m2 the year prior to treatment. Following treatment, a significant reduction (p < 0.001) in eGFR decline was observed (6.3 ml/min/1.73m2). Furthermore, a significant improvement in proteinuria was observed upon treatment (p < 0.001). Sixty-two percent (n = 43) of the patients were considered a responder and showed considerable slowing of graft function deterioration in the year after treatment (p < 0.001). Three and 5-year graft survival was significantly superior in responders. Conclusions More than 60% of patients with c-aABMR with a progressive decline in eGFR respond favorably to treatment with IVIG-MP resulting in a significant improvement of graft survival (Sablik, Am J Transplant 18, 2018).http://link.springer.com/article/10.1186/s12882-019-1385-zTransplantationRenal allograft rejectionC-aABMRIVIGMPTreatment |
spellingShingle | Kasia A. Sablik Marian C. Clahsen-van Groningen Caspar W. N. Looman Jeffrey Damman Madelon van Agteren Michiel G. H. Betjes Treatment with intravenous immunoglobulins and methylprednisolone may significantly decrease loss of renal function in chronic-active antibody-mediated rejection BMC Nephrology Transplantation Renal allograft rejection C-aABMR IVIG MP Treatment |
title | Treatment with intravenous immunoglobulins and methylprednisolone may significantly decrease loss of renal function in chronic-active antibody-mediated rejection |
title_full | Treatment with intravenous immunoglobulins and methylprednisolone may significantly decrease loss of renal function in chronic-active antibody-mediated rejection |
title_fullStr | Treatment with intravenous immunoglobulins and methylprednisolone may significantly decrease loss of renal function in chronic-active antibody-mediated rejection |
title_full_unstemmed | Treatment with intravenous immunoglobulins and methylprednisolone may significantly decrease loss of renal function in chronic-active antibody-mediated rejection |
title_short | Treatment with intravenous immunoglobulins and methylprednisolone may significantly decrease loss of renal function in chronic-active antibody-mediated rejection |
title_sort | treatment with intravenous immunoglobulins and methylprednisolone may significantly decrease loss of renal function in chronic active antibody mediated rejection |
topic | Transplantation Renal allograft rejection C-aABMR IVIG MP Treatment |
url | http://link.springer.com/article/10.1186/s12882-019-1385-z |
work_keys_str_mv | AT kasiaasablik treatmentwithintravenousimmunoglobulinsandmethylprednisolonemaysignificantlydecreaselossofrenalfunctioninchronicactiveantibodymediatedrejection AT mariancclahsenvangroningen treatmentwithintravenousimmunoglobulinsandmethylprednisolonemaysignificantlydecreaselossofrenalfunctioninchronicactiveantibodymediatedrejection AT casparwnlooman treatmentwithintravenousimmunoglobulinsandmethylprednisolonemaysignificantlydecreaselossofrenalfunctioninchronicactiveantibodymediatedrejection AT jeffreydamman treatmentwithintravenousimmunoglobulinsandmethylprednisolonemaysignificantlydecreaselossofrenalfunctioninchronicactiveantibodymediatedrejection AT madelonvanagteren treatmentwithintravenousimmunoglobulinsandmethylprednisolonemaysignificantlydecreaselossofrenalfunctioninchronicactiveantibodymediatedrejection AT michielghbetjes treatmentwithintravenousimmunoglobulinsandmethylprednisolonemaysignificantlydecreaselossofrenalfunctioninchronicactiveantibodymediatedrejection |